Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemtuzumab Ozogamicin Dose Schedules in High-Risk MDS
NCT00022321Phase 2Unknown
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Sep 2001
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of gemtuzumab ozogamicin in myelodysplastic syndrome (MDS) (2 arms), sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoint: Total Survival. Status: unknown.
02
Drugs
gemtuzumab ozogamicin
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00022321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00022321.